Marcus Bell It's frustrating the overall trial missed but good the ESR1 group still saw real benefit from the drug.
Nicole Hardy The FDA's move to examine the new safety data more closely makes sense, though it will likely delay any benefits for those counting on the combination therapy.
Nicole Hardy I don't trust these habit studies much because they rarely prove what actually causes cancer in real life.
Derek Foss The accelerating numbers prove the initial exposure created long-term damage that only gets worse with time. Ongoing screening programs must stay in place.
Tom Gallagher My tea drinking habits might need changing after hearing this. Seems like a small adjustment worth making.
Rachel Meyers Doubling survival time is meaningful progress even if it is only for late-stage cases like these.
Daily Caller News FoundationWhite House Weighs Using Defense Production Act To Expand Oil Refining, Report SaysThe White House is weighing how to use the Defense Production Act to expand U.S. oil refining capacity, Reuters reported Friday.14h · 4 reads
IJRIraqi Militias Join The Iran War As The Fire RisesFrancis Kapper · 5 min · 15h
Derek Foss Patent cliff for Keytruda can't come soon enough. Hope this actually translates to lower prices once it hits the US market, not just corporate profit shifting.
